Contineum Therapeutics/$CTNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Contineum Therapeutics
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Ticker
$CTNM
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
41
ISIN
US21217B1008
Website
CTNM Metrics
BasicAdvanced
$104M
-
-$1.98
-
-
Price and volume
Market cap
$104M
52-week high
$22.00
52-week low
$3.35
Average daily volume
142K
Financial strength
Current ratio
21.47
Quick ratio
21.311
Long term debt to equity
2.461
Total debt to equity
3.248
Profitability
EBITDA (TTM)
-58.799
Management effectiveness
Return on assets (TTM)
-22.94%
Return on equity (TTM)
-33.03%
Valuation
Price to book
0.56
Price to tangible book (TTM)
0.56
Price to free cash flow (TTM)
-2.548
Free cash flow yield (TTM)
-39.24%
Free cash flow per share (TTM)
-157.35%
Growth
Earnings per share change (TTM)
-40.91%
What the Analysts think about CTNM
Analyst ratings (Buy, Hold, Sell) for Contineum Therapeutics stock.
CTNM Financial Performance
Revenues and expenses
CTNM Earnings Performance
Company profitability
CTNM News
AllArticlesVideos
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Business Wire·3 days ago
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Business Wire·1 month ago
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Contineum Therapeutics stock?
Contineum Therapeutics (CTNM) has a market cap of $104M as of June 28, 2025.
What is the P/E ratio for Contineum Therapeutics stock?
The price to earnings (P/E) ratio for Contineum Therapeutics (CTNM) stock is 0 as of June 28, 2025.
Does Contineum Therapeutics stock pay dividends?
No, Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Contineum Therapeutics dividend payment date?
Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Contineum Therapeutics?
Contineum Therapeutics (CTNM) does not currently have a Beta indicator.